620 results on '"White, Deborah L."'
Search Results
2. Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions
3. Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia
4. Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
5. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia
6. HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort
7. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota
8. Synergy of Ruxolitinib and Carfilzomib in Targeting the PAX5::JAK2 fusion I n Vitro: Potential Therapeutic Advantage for a Subset of Ph-like Acute Lymphoblastic Leukemia
9. Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
10. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
11. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
12. The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL
13. Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients
14. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
15. Status of Solidago albopilosa Braun (White-Haired Goldenrod) [Asteraceae], a Kentucky Endemic
16. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions
17. Case report: Rare case of donor cell‐derived T‐cell acute lymphoblastic leukaemia in a female patient after receiving an allo‐transplant from her male sibling
18. Gain of chromosome 21 increases the propensity for P2RY8::CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression
19. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
20. Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy
21. Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression
22. Supplementary Table S5 from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia
23. Data from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia
24. Supplementary Methods and References from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia
25. Supplementary Figures S1-S9 from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia
26. Supplementary Figure Legends from Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia
27. Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines
28. Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia
29. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
30. PTPN11 Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph+ ALL Cells, but Are Sensitive to the Combination
31. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients
32. RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)
33. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells
34. Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten
35. JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies
36. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
37. Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia
38. Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis
39. Two novel cases of NUTM1 ‐rearranged B‐cell acute lymphoblastic leukaemia presenting with high‐risk features
40. HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort
41. B‐cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification
42. Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis
43. HMGN1 expression Predisposes Down Syndrome Patients to Develop P2RY8-CRLF2 acute Lymphoblastic Leukemia
44. Identification of a novel GOLGA4–JAK2 fusion gene in B‐cell acute lymphoblastic leukaemia
45. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia
46. A Flora of Gold Head Branch Ravine and Adjacent Uplands, Clay County, Florida
47. Landscape History and Changes in Sandhill Vegetation in North-Central and South-Central Florida
48. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
49. Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy
50. Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.